Home Uncategorized

Uncategorized

Random

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Psychedelic Spotlight: Entheon Biomedical

PsyCap Recap: 3 Key Takeaways From the January 2021 Mindset Pharma...

atai Life Sciences Announces R&D Day Agenda

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late...

atai Life Sciences to Participate in Upcoming March Investor Conferences

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS)...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

The Reddit Revolution Riles up Retail Investors: How Short Selling Gamestop...

Stephen Bardin to Join atai Life Sciences as CFO Designate

12 3...13 Page 1 of 13

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.